ADALIMUMAB (HUMIRA)

Course overview

Adalimumab is U.S. FDA-approved to treat ankylosing spondylitis, moderate/severe Crohn disease refractory to conventional therapy in patients who are unresponsive to/intolerant of infliximab, chronic moderate/severe plaque psoriasis, psoriatic arthritis, moderate/severe rheumatoid arthritis, and juvenile idiopathic arthritis in patients ≥ 4 years. This continuing education module is designed to give the reader/learner an increased understanding of adalimumab. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.